- Home
- PTGX vs IMCR Comparison
PTGX vs IMCR Comparison
Compare PTGX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | IMCR |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 1.8B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PTGX | IMCR |
|---|---|---|
| Price | $82.71 | $32.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $93.00 | $65.33 |
| AVG Volume (30 Days) | ★ 946.7K | 284.1K |
| Earning Date | 02-20-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | $209,217,000.00 | ★ $379,590,000.00 |
| Revenue This Year | N/A | $32.28 |
| Revenue Next Year | $288.98 | $10.66 |
| P/E Ratio | $116.88 | ★ N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $33.70 | $23.15 |
| 52 Week High | $96.54 | $40.72 |
Technical Indicators
Market Signals| Indicator | PTGX | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.73 | 33.75 |
| Support Level | $84.11 | $34.00 |
| Resistance Level | $89.61 | $34.97 |
| Average True Range (ATR) | 3.12 | 1.40 |
| MACD | -0.98 | -0.43 |
| Stochastic Oscillator | 0.92 | 4.11 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.